AVITA Medical to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
AVITA Medical (NASDAQ: RCEL) has announced its participation in the upcoming Piper Sandler 36th Annual Healthcare Conference. CEO Jim Corbett will deliver a presentation on Tuesday, December 3, 2024, at 11:30 a.m. Eastern Time. The company, which specializes in regenerative medicine and first-in-class devices for wound care management and skin restoration, will provide a live webcast of the fireside chat through their investor relations website. The presentation will remain available for replay after the event concludes.
AVITA Medical (NASDAQ: RCEL) ha annunciato la sua partecipazione al 36° Annual Healthcare Conference di Piper Sandler. Il CEO Jim Corbett presenterà un discorso martedì 3 dicembre 2024, alle 11:30 a.m. ora orientale. L'azienda, specializzata in medicina rigenerativa e dispositivi innovativi per la gestione delle ferite e il ripristino della pelle, offrirà una diretta web del colloquio informale attraverso il proprio sito web delle relazioni con gli investitori. La presentazione rimarrà disponibile per la visione anche dopo la conclusione dell'evento.
AVITA Medical (NASDAQ: RCEL) ha anunciado su participación en la 36ª Conferencia Anual de Atención Médica de Piper Sandler. El CEO Jim Corbett realizará una presentación el martes 3 de diciembre de 2024, a las 11:30 a.m. hora del Este. La empresa, especializada en medicina regenerativa y dispositivos de primera clase para el manejo de heridas y la restauración de la piel, proporcionará una transmisión en vivo de la charla a través de su sitio web de relaciones con inversores. La presentación estará disponible para su reproducción después de que concluya el evento.
AVITA Medical (NASDAQ: RCEL)은 Piper Sandler 제36회 연례 의료 컨퍼런스에 참가한다고 발표했습니다. CEO 짐 코르벳(Jim Corbett)은 2024년 12월 3일 화요일 동부 표준시 기준 오전 11:30에 발표를 진행할 예정입니다. 이 회사는 재생 의료 및 상처 관리와 피부 복원을 위한 일류 장치를 전문으로 하며, 투자자 관계 웹사이트를 통해 화상 채팅의 생중계를 제공할 것입니다. 발표 후 이벤트가 종료된 후에도 다시 시청할 수 있습니다.
AVITA Medical (NASDAQ: RCEL) a annoncé sa participation à la 36e Conférence Annuelle sur la Santé de Piper Sandler. Le PDG Jim Corbett présentera une communication le mardi 3 décembre 2024, à 11h30, heure de l'Est. L'entreprise, spécialisée dans la médecine régénérative et des dispositifs de première classe pour la gestion des plaies et la restauration de la peau, proposera un webinaire en direct de la discussion sur son site Web de relations avec les investisseurs. La présentation sera également disponible en rediffusion après la fin de l'événement.
AVITA Medical (NASDAQ: RCEL) hat seine Teilnahme an der 36. jährlichen Gesundheitskonferenz von Piper Sandler bekannt gegeben. CEO Jim Corbett wird am Dienstag, den 3. Dezember 2024, um 11:30 Uhr Eastern Time eine Präsentation halten. Das Unternehmen, das auf regenerative Medizin und erstklassige Geräte für die Wundversorgung und Hautrestaurierung spezialisiert ist, wird eine Live-Webcast der informellen Gesprächsrunde über seine Investor-Relations-Website anbieten. Die Präsentation wird nach Abschluss der Veranstaltung auch als Wiederholung verfügbar sein.
- None.
- None.
VALENCIA, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 11:30 a.m. Eastern Time.
A live webcast of the fireside chat will be accessible under the Events & Presentations section of the Company's website at https://ir.avitamedical.com. A replay of the webcast will be available following the conclusion of the event.
About AVITA Medical, Inc.
AVITA Medical® is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. In the United States, AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
FAQ
When will AVITA Medical (RCEL) present at the Piper Sandler Healthcare Conference 2024?
How can I watch AVITA Medical's (RCEL) presentation at the Piper Sandler Conference?
What is AVITA Medical's (RCEL) main business focus?
Which stock exchanges is AVITA Medical listed on?
